Anika Therapeutics - ANIK Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $29.50
  • Forecasted Upside: 16.00%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$25.43
▼ -0.26 (-1.01%)

This chart shows the closing price for ANIK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Anika Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ANIK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ANIK

Analyst Price Target is $29.50
▲ +16.00% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Anika Therapeutics in the last 3 months. The average price target is $29.50, with a high forecast of $37.00 and a low forecast of $22.00. The average price target represents a 16.00% upside from the last price of $25.43.

This chart shows the closing price for ANIK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 2 contributing investment analysts is to moderate buy stock in Anika Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/25/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/24/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/22/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/14/2024StephensReiterated RatingEqual Weight ➝ Equal Weight$22.00N/A
3/14/2024Barrington ResearchBoost TargetOutperform ➝ Outperform$29.00 ➝ $37.00Low
1/3/2024Barrington ResearchBoost TargetOutperform ➝ Outperform$28.00 ➝ $29.00Low
11/3/2023Barrington ResearchBoost TargetOutperform ➝ Outperform$24.00 ➝ $28.00Low
8/14/2023Barrington ResearchUpgradeMarket Perform ➝ Outperform$24.00Low
8/10/2023StephensLower TargetEqual Weight ➝ Equal Weight$28.00 ➝ $23.00N/A
4/14/2023StephensReiterated RatingEqual Weight$28.00Low
3/7/2023Barrington ResearchDowngradeOutperform ➝ Market PerformLow
11/9/2022Barrington ResearchUpgradeMarket Perform ➝ Outperform$31.00Low
10/14/2022StephensReiterated RatingEqual Weight$26.00Low
10/13/2022StephensInitiated CoverageEqual WeightLow
3/9/2022Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
3/9/2022StephensDowngradeOverweight ➝ Equal Weight$35.00High
11/15/2021StephensInitiated CoverageOverweight$55.00Medium
11/5/2021Barrington ResearchBoost TargetOutperform$44.00 ➝ $48.00Medium
7/16/2021UBS GroupInitiated CoverageNeutral$46.00Low
12/16/2020Barrington ResearchUpgradeMarket Perform ➝ Outperform$43.00High
5/8/2020Barrington ResearchDowngradeOutperform ➝ Market PerformHigh
2/21/2020Barrington ResearchReiterated RatingBuy$60.00Low
1/21/2020SidotiUpgradeNeutral ➝ Buy$61.00Low
1/10/2020First AnalysisUpgradeOutperform ➝ Strong-Buy$65.00Low
11/5/2019BWS FinancialInitiated CoverageSell$29.00High
10/25/2019SidotiSet TargetHold$50.00N/A
9/24/2019Barrington ResearchReiterated RatingOutperform$49.00 ➝ $58.00Medium
9/23/2019First AnalysisDowngradeStrong-Buy ➝ Outperform$54.00Low
7/25/2019Barrington ResearchReiterated RatingBuy$45.00 ➝ $49.00High
7/25/2019First AnalysisUpgradeNeutral ➝ Strong-Buy$37.00 ➝ $54.00High
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.16 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/22/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/21/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/21/2023
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/20/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/19/2024
  • 8 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/20/2024
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Anika Therapeutics logo
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.
Read More

Today's Range

Now: $25.43
Low: $25.37
High: $25.81

50 Day Range

MA: $25.23
Low: $23.31
High: $26.42

52 Week Range

Now: $25.43
Low: $16.54
High: $28.58

Volume

83,322 shs

Average Volume

82,151 shs

Market Capitalization

$377.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Anika Therapeutics?

The following Wall Street research analysts have issued reports on Anika Therapeutics in the last year: Barrington Research, Stephens, and StockNews.com.
View the latest analyst ratings for ANIK.

What is the current price target for Anika Therapeutics?

2 Wall Street analysts have set twelve-month price targets for Anika Therapeutics in the last year. Their average twelve-month price target is $29.50, suggesting a possible upside of 16.0%. Barrington Research has the highest price target set, predicting ANIK will reach $37.00 in the next twelve months. Stephens has the lowest price target set, forecasting a price of $22.00 for Anika Therapeutics in the next year.
View the latest price targets for ANIK.

What is the current consensus analyst rating for Anika Therapeutics?

Anika Therapeutics currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for ANIK.

What other companies compete with Anika Therapeutics?

How do I contact Anika Therapeutics' investor relations team?

Anika Therapeutics' physical mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company's listed phone number is (781) 457-9000 and its investor relations email address is [email protected]. The official website for Anika Therapeutics is www.anikatherapeutics.com. Learn More about contacing Anika Therapeutics investor relations.